Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus

Angiology

Volumn 62, Issue 4, 2011, Pages 291-295

  Papanas, N ^a   Katsiki, N ^b   Papatheodorou, K ^a   Demetriou, M ^a   Papazoglou, D ^a   Gioka, T ^c   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

C reactive protein; lipids; peripheral neuropathy; type 2 diabetes mellitus; uric acid; vascular disease

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY DISABILITY SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; URIC ACID;

EID: 79953884729     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710394164     Document Type: Article

References (47)

1. Forouhi NG, Merrick D., Goyder E., et al;. Diabetes prevalence in England, 2001-estimates from an epidemiological model. Diabet Med. 2006 ; 23 (2). 189-197.
2. Yang W., Lu J., Weng J., et al;. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362 (12). 1090-1101.
3. Boulton AJ, Vinik AI, Arezzo JC, et al;. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005 ; 28 (4). 956-962. (Pubitemid 40434506)
4. Várkonyi T., Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008 ; 10 (2). 99-108.
5. Sugimoto K., Murakawa Y., Sima AA Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev. 2000 ; 16 (6). 408-433.
6. Tesfaye S., Chaturvedi N., Eaton SE, et al;. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 ; 352 (4). 341-350.
7. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 ; 31 (3). 464-469.
8. Habib AA, Brannagan TH III. Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep. 2010 ; 10 (2). 92-100.
9. Barbosa AP, Medina JL, Ramos EP, Barros HP Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes Metab. 2001 ; 27 (4pt1). 496-502. (Pubitemid 32852459)
10. Papanas N., Papatheodorou K., Papazoglou D., Kotsiou S., Christakidis D., Maltezos E. An insertion/deletion polymorphism in the alpha2B adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007 ; 115 (5). 327-330. (Pubitemid 46877867)
11. Yano K., Reed DM, Mcgee DL Ten-year incidence of coronary heart disease in the Honolulu heart program. Relationship to biologic and lifestyle characteristics. Am J Epidemiol. 1984 ; 119 (5). 653-666.
12. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. Am J Epidemiol. 1995 ; 141 (7). 637-644.
13. Moriarity JT, Folsom AR, Iribarren C., Nieto FJ, Rosamond WD Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2000 ; 10 (3). 136-143. (Pubitemid 30171270)
14. Fang J., Alderman MH Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971- 1992. National health and nutrition examination survey. JAMA. 2000 ; 283 (18). 2404-2410. (Pubitemid 30257539)
15. Mazza A., Pessina AC, Pavei A., Scarpa R., Tikhonoff V., Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol. 2001 ; 17 (12). 1097-1104.
16. Daskalopoulou SS, Athyros VG, Elisaf M., Mikhailidis DP Uric acid levels and vascular disease. Curr Med Res Opin. 2004 ; 20 (6). 951-954. (Pubitemid 38821534)
17. Edwards NL The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009 ; 21 (2). 132-137.
18. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K., Mikhailidis DP, Elisaf MS Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med. 2005 ; 258 (5). 435-441. (Pubitemid 41546559)
19. Karagiannis A., Mikhailidis DP, Tziomalos K., et al;. Serum uric acid as an independent predictor of early death after acute stroke. Circ J. 2007 ; 71 (7). 1120-1127. (Pubitemid 46998030)
20. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007 ; 58 (4). 450-457. (Pubitemid 47301052)
21. Shankar A., Klein BE, Nieto FJ, Klein R. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis. 2008 ; 196 (2). 749-755. (Pubitemid 351146654)
22. Papazafiropoulou A., Tentolouris N., Moyssakis I., Perrea D., Katsilambros N. The potential effect of some newer risk factors for atherosclerosis on aortic distensibility in subjects with and without type 2 diabetes. Diabetes Care. 2006 ; 29 (8). 1926-1928. (Pubitemid 44156656)
23. Lehto S., Niskanen L., Ronnemaa T., Laakso M. Serum uric acid is a strong predictor of stroke in patients with noninsulin-dependent diabetes mellitus. Stroke. 1998 ; 29 (3). 635-639. (Pubitemid 28145791)
24. Tseng CH Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med. 2004 ; 21 (7). 724-729.
25. Daskalopoulou SS, Tzovaras V., Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005 ; 11 (32). 4161-4175. (Pubitemid 41679180)
26. Young MJ, Boulton AJM, McLeod AF, Williams DRR, Sonksen PH A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993 ; 36 (2). 150-154. (Pubitemid 23034314)
27. Paisley AN, Abbott CA, van Schie CH, Boulton AJM A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med. 2002 ; 19 (5). 400-405. (Pubitemid 34534215)
28. Papanas N., Papatheodorou K., Papazoglou D., Monastiriotis C., Christakidis D., Maltezos E. A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008 ; 116 (2). 135-138. (Pubitemid 351363386)
29. Joint National Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ; 289 (19). 2560-2572.
30. Blackburn H., Keys A., Simonson E., Rantaharju PM, Punsar S. The electrocardiogram in population studies. A classification system. Circulation. 1960 ; 21: 1160-1175.
31. Molitch ME, DeFronzo RA, Franz MJ, et al;. Diabetic nephropathy. Position statement. Diabetes Care. 2003 ; 26 (suppl 1). S94 - S98.
32. Fong DS, Aiello L., Gardner TW, et al;. Diabetic retinopathy. Position statement. Clinical Practice Recommendations 2003. Diabetes Care. 2003 ; 26 (supp 1): S99 - S102.
33. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander ? Metabolism. 2006 ; 55 (10). 1293-1301. (Pubitemid 44354944)
34. Herder C., Lankisch M., Ziegler D., et al; Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care. 2009 ; 32 (4). 680-682.
35. Lanza GA, Pitocco D., Navarese EP, et al;. Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. Eur Heart J. 2007 ; 28 (7). 814-820. (Pubitemid 47343595)
36. González-Clemente JM, Vilardell C., Broch M., et al;. Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes. Eur J Endocrinol. 2007 ; 157 (1). 31-38. (Pubitemid 47162563)
37. Wiggin TD, Sullivan KA, Pop-Busui R., Amato A., Sima AA, Feldman EL Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009 ; 58 (7). 1634-1640.
38. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A., Pennathur S., Feldman EL Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes. 2009 ; 58 (10). 2376-2385.
39. Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 ; 348 (5). 383-393. (Pubitemid 36159355)
40. Vincent AM, Hinder LM, Pop-Busui R., Feldman EL Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009 ; 14 (4). 257-267.
41. Strazzullo P., Puig JG Uric acid and oxidative stress: relative impact on cardiovascular risk ? Nutr Metab Cardiovasc Dis. 2007 ; 17 (6). 409-414.
42. So A., Thorens B. Uric acid transport and disease. J Clin Invest. 2010 ; 120 (6). 1791-1799.
43. Mora S., Ridker PM Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 ; 97 (2A). 33A - 41A. (Pubitemid 43139718)
44. Athyros VG, Elisaf M., Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004 ; 43 (4). 589-599. (Pubitemid 38401873)
45. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359 (15). 1577-1589.
46. Fioretto P., Dodson PM, Ziegler D., Rosenson RS Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010 ; 6 (1). 19-25.
47. Kles KA, Vinik AI Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev. 2006 ; 2 (2). 131-145. (Pubitemid 44082935)